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Differential microRNA regulation of HLA-C
expression and its association with HIV control
Smita Kulkarni1,2*, Ram Savan3*, Ying Qi1,2, Xiaojiang Gao1,2, Yuko Yuki1,2, Sara E. Bass1, Maureen P. Martin1,2, Peter Hunt4,
Steven G. Deeks4, Amalio Telenti5, Florencia Pereyra2, David Goldstein6, Steven Wolinsky7, Bruce Walker2, Howard A. Young3
& Mary Carrington1,2
TheHLA-C locus is distinct relative to the other classical HLA class
I loci in that it has relatively limited polymorphism1, lower expres-
sion on the cell surface2,3, and more extensive ligand–receptor
interactions with killer-cell immunoglobulin-like receptors4. A
single nucleotide polymorphism (SNP) 35 kb upstream of HLA-C
(rs9264942; termed 235) associates with control of HIV5–7, and
with levels of HLA-C messenger RNA transcripts8 and cell-surface
expression7, but the mechanism underlying its varied expression is
unknown. We proposed that the235 SNP is not the causal variant
for differential HLA-C expression, but rather is marking another
polymorphism that directly affects levels of HLA-C7. Here we show
that variation within the 39 untranslated region (UTR) of HLA-C
regulates binding of the microRNA hsa-miR-148 to its target site,
resulting in relatively low surface expression of alleles that bind
this microRNA and high expression of HLA-C alleles that escape
post-transcriptional regulation. The 39UTR variant associates
strongly with control of HIV, potentially adding to the effects of
genetic variation encoding the peptide-binding region of the HLA
class I loci. Variation in HLA-C expression adds another layer of
diversity to this highly polymorphic locus that must be considered
when deciphering the function of these molecules in health and
disease.
MicroRNAs (miRNAs) are a class of non-protein-codingRNAs that
are estimated to regulate 30% of all genes in animals9 by binding to
specific sites in the 39UTR, resulting in post-transcriptional repres-
sion, cleavage or destabilization10–12. The 39UTR of theHLA-C gene is
predicted to be a target for 26 distinct human miRNAs using three
miRNA-target-prediction programs (Supplementary Fig. 1), of which
three (miR-148a and miR-148b, which bind the same target site, and
miR-657) were shown to have the greatest likelihood of binding. We
sequenced the 39UTRs of the commonHLA-C alleles (Supplementary
Fig. 2) and show that the two binding sites of these three miRNAs are
polymorphic (Supplementary Fig. 3a). The binding site for miR-148a/
miR-148b contains a single base pair insertion/deletion at position 263
downstream of theHLA-C stop codon (rs67384697G representing the
insertion (263ins) and rs673846972 representing the deletion
(263del)) along with other precisely linked variants (259C/T, 261T/
C, 266C/T). These variants are likely to impose a restriction in miR-
148a/miR-148b binding, as prediction algorithms indicate that the
binding of thesemiRNAs to the alleles marked by 263ins (for example,
Cw*0702, a low-expression allotype) is more stable than to alleles with
263del (for example, Cw*0602, a high-expression allotype) (Sup-
plementary Fig. 3b). Similarly, alleles with 307C within the miR-657
target site are predicted to be better targets of miR-657 than those
with 307T (Supplementary Fig. 4). Thus, variation in the 39UTR of
HLA-Cmay influence the interaction between thesemiRNAs and their
putative binding sites in an allele-specific manner, potentially leading
to differential levels of HLA-C allotype expression.
To test directly whether the variation in the HLA-C 39UTR affects
levels of protein expression, the full-length 39UTRs containing intact
miR-148a/miR-148b- and miR-657-binding sites (that is, 263ins and
307C, respectively; Cw*0702, Cw*0303, Cw*0401, Cw*0701) and dis-
rupted binding sites (that is, 263del and 307T, respectively; Cw*0602,
Cw*0802, Cw*1203, Cw*1502) were each cloned downstream of the
luciferase gene in a pGL3 reporter construct (Fig. 1a). The constructs
were then transfected into HLA class I negative B721.221 cells, and the
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Figure 1 | Variation in the HLA-C 39UTR differentially affects the
expression of a reporter gene. a, b, Full-length 39UTRs of various HLA-C
alleles cloned into luciferase (LUC) reporter constructs were transfected into
B721.221 cell lines and the stability of the mRNA was estimated by dual
luciferase reporter assays. The normalized luciferase activity is presented as fold
change of relative light units (RLU). The data represent six replicates in each
experimental group, themean6 standard error (s.e.) are depicted as horizontal
and vertical bars for each group, respectively, and one of three comparable
experiments performed is shown. Non-parametric Wilcoxon–Mann–Whitney
tests were used for statistical comparisons and two-tailed P values are indicated.
NS, not significant. a, Schematic representations of the luciferase reporter
constructs used in this study. Sv40, Simian virus 40. b, Fold change in luciferase
activity of 39 UTRs of HLA-C alleles as compared to that of Cw*0602.
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level of luciferase activity was measured (fold increase of relative light
units). Although the Cw*0602 39UTR repressed luciferase activity as
compared to the control containing no 39UTR, the constructs contain-
ing intact miRNA-binding sites (that is, 263ins and 307C; Cw*0702,
Cw*0303,Cw*0401, Cw*0701) produced significantly lower luciferase
activity relative to the construct containing the 39UTR of Cw*0602,
which contains 263del and 307T (Fig. 1b). However, 39UTRs from
other alleles with the 263del and 307T variants (Cw*0802, Cw*1203,
Cw*1502) did not show significant variation in luciferase activity as
compared toCw*0602 (Fig. 1b). Psicheck2 reporter constructs contain-
ing 39UTRs of Cw*0602 also produced significantly higher luciferase
activity as compared to those with Cw*0702 39UTR (Supplementary
Fig. 5a), indicating that this effectwas reproducible in a distinct reporter
construct. Further, pGL3 constructs containing 39UTRs of Cw*0602
and Cw*0702 in three additional cell lines showed the same pattern as
that seen in B721.221 cells, indicating a consistent difference of these
39UTRs in the regulation of HLA-C expression that is independent of
cell type (Supplementary Fig. 5b–e). Thus,HLA-C 39UTR alleles char-
acterized by variation at positions 263 and 307withinmiRNA-binding
regions differentially regulate gene expression.
The expression of endogenous mature miR-148b and miR-152,
another miR-148 miRNA family member, was very low as compared
tomiR-148a, andmiR-657 was undetectable inHLA-C homozygous B
lymphoblastoid cell lines (BLCLs) and B721.221 cells (Supplementary
Fig. 6). These data point to the involvement of miR-148a rather than
miR-148b, miR-152, or miR-657 in regulation of HLA-C expression.
Additionally, disruption of the miR-657-binding site by site-directed
mutagenesis had no effect on luciferase activity (Supplementary Fig.
7a, b), indicating that miR-657 does not affect HLA-C expression.
To test whether variants in the miR-148a-binding site account for
the differential gene expression patterns, we swapped positions 256–
266 of the 39UTR of Cw*0602 to match those of Cw*0702 and vice
versa, thereby providing an intactmiR-148a-binding site to the 39UTR
of Cw*0602 (06mut) and disrupting the binding site for miR-148a in
theCw*0702 39UTR (07mut), but leaving the remainder of the 39UTR
sequences intact (Fig. 2a). The luciferase activity of 06mut was signifi-
cantly lower than that of 07mut (Fig. 2b), indicating that the poly-
morphisms between positions 256–266 in the miR-148a-binding
region account for the difference in luciferase expression between
constructs containing the 39UTRs of Cw*0602 versus Cw*0702.
Two other polymorphic sites, A256C and A267G, in the miR-148a-
binding site (Supplementary Fig. 3a) distinguish different sets of alleles
as compared to 263del/ins, but these two variants had no effect on
miRNA-mediated suppression (Supplementary Fig. 7c, d).
Further validation of the differential regulation of HLA-C alleles by
miR-148a was achieved by co-transfection of B221.227 cell lines with
either a mimic or an inhibitor of miR-148a along with a luciferase
reporter construct that contained the 39UTR with 263ins (Cw*0702
or 06mut) or with 263del (Cw*0602 or 07mut). The normalized luci-
ferase activity in cells transfected with the constructs containing the
263del allele (Cw*0602 and 07mut 39UTR) was not significantly
altered by co-transfection with either the mimic or the inhibitor
(Fig. 2c, d). However, the mimic of miR-148a further repressed luci-
ferase activity in cells transfected with the 263ins allele (Cw*0702 and
06mut 39UTR), whereas co-transfection with inhibitor rescued the
suppression significantly (Fig. 2c, d). These data provide further sup-
port for allele-specific miR-148a targeting of the HLA-C 39UTR.
BLCLs from individuals homozygous for either Cw*0602 (BLCL-
Cw*0602Hom) or Cw*0702 (BLCL-Cw*0702Hom) were used to
determine whether the variation in themiR-148a-binding site affected
endogenousHLA-C expression on the cell surface. As described previ-
ously, overall HLA-C expression on a Cw*0602 homozygous cell line
was higher than that on aCw*0702 homozygous cell line. As expected,
transfection with mimics or inhibitors of miR-148a (Fig. 3a) andmiR-
148b (Fig. 3b) had no significant effect on cell-surface expression of
Cw*0602, an allele containing 263del in the 39UTR that disrupts
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Figure 2 | Disruption ofmiR-148a target site rescues suppression. a, Partial
sequence of mutated 39UTRs of Cw*0602 and Cw*0702 (06mut and 07mut,
respectively) are aligned to 39UTR sequences of nativeCw*0602 andCw*0702.
Identical nucleotides are shown as dots, altered nucleotides are underlined, and
deletions are indicated by dashes for optimal alignment. b, Fold change in
luciferase activity of themodified 39UTR (06mut and 07mut). c, Fold change in
luciferase activity of reporters containing wild-type Cw*0602 or Cw*0702
39UTR sequences upon introduction ofmiR-148amimic and inhibitor. d, Fold
change in luciferase activity of reporters containing 06mut and 07mut 39UTR
sequences upon introduction of miR-148a mimic and inhibitor. Presence (1)
or absence (2) of each variable, including a negative control (NC) miRNA, a
mimic of miR-148a, or an inhibitor of miR-148a is shown. The data represent
six replicates in each experimental group, the mean6 s.e. are depicted as
horizontal and vertical bars for each group, respectively, and one of three
comparable experiments performed is shown. Non-parametric Wilcoxon–
Mann–Whitney tests were used for statistical comparisons and two-tailed P
values are indicated.
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miR-148a/miR-148b binding. However, transfection of either miR-
148a or miR-148b mimic resulted in decreased expression of
Cw*0702 relative to cells transfected with a negative control (Fig. 3c
and d, respectively), indicating that increased levels of either of these
miRNAs can further downregulate HLA-C expression of alleles that
contain an intact binding site for miR-148a/miR-148b (263ins), such
as Cw*0702. The inhibitor of miR-148a significantly increased the
level of endogenous Cw*0702 expression, but the inhibitor of miR-
148b had no effect on expression of Cw*0702 (Fig. 3c and d, respec-
tively), confirming the very low levels of miR-148b endogenous
expression (Supplementary Fig. 6).
The differential miR-148a regulation of expression across HLA-C
alleles was precisely reflected in experiments involving: (1) additional
HLA-C homozygous BLCLs (Supplementary Fig. 8a, b); (2) use of
another form of miR-148a inhibitor (peptide nucleic acid inhibitor;
Supplementary Fig. 8c); and (3) analysis of total cellularHLA-C protein
as determined by western blot (Supplementary Figs 9, 10 and Sup-
plementary Note 1). We conclude that miR-148a regulates the expres-
sion of HLA-C in an allele-specific manner that is dependent on
variation in the miR-148a-binding site of the HLA-C 39UTR.
ThemiR-148a-binding site of theHLA-C 39UTR is in strong linkage
disequilibrium with the 235 SNP that was shown to associate with
control of HIV and HLA-C expression levels5–7 (D95 0.75, r2 5 0.74;
P, 0.0001, N5 1,760). Although there is no explanation for a direct
causal effect of 235 variation on HLA-C expression7, the interaction
between miR-148a and its polymorphic binding site in the 39UTR of
HLA-C presents a clear rationale for variable levels of HLA-C expres-
sion. We determined the frequencies of the 263del/ins genotypes in a
cohort of 2,527 HIV-infected European American individuals.
Subjects with mean plasma viral loads of,2,000 copies of viral RNA
perml of plasma (controllers) were enriched for 263del, whereas those
with viral loads of .10,000 copies of viral RNA per ml of plasma
(noncontrollers) had a significantly higher frequency of 263ins
(Supplementary Table 1). Because of the strong linkage disequilibrium
across the HLA-C and HLA-B genes (Supplementary Tables 2, 3), we
determined whether the 39UTR variant has an effect on HIV control
that is independent of individual HLA-A, B, or C alleles. A logistic
regression approach with stepwise selection of the HLA-C 39UTR
263 variant along with all HLA-A, B and C alleles that have$1%
frequency in our cohort (63 alleles) was used. In this analysis, the
263del/del versus 263ins/ins comparison remains significant along
with 5 of the 63 HLA alleles (B*5701, B*5703, B*2705, B*5801 and
Cw*1402; Table 1; for frequencies, see Supplementary Table 1).
Although these data indicate that the 39UTR del/ins variant has an
independent effect on HIV control (see Supplementary Note 2 for
potential mechanisms that could explain the association), we still
cannot completely rule out the possibility that the strong linkage dis-
equilibrium in the region is confounding the results13 (Supplementary
Table 4 and Supplementary Note 3).
The extensive number of disease associationswithHLA class I and II
genes has largely been ascribed to the polymorphic peptide-binding
amino acid positions of thesemolecules. Some reports have speculated
that gene expression14 and/or splicing patterns of the HLA genes15,16
may have a role, but convincing data aremissing. Of interest, theHLA-
G 39UTR was shown to encode a polymorphic target site for miR-
148a/b17,18. Levels ofHLA-Ghave been suggested to alter risk of asthma
in children of mothers with asthma18, although the specificity of assays
reporting HLA-G expression beyond implanting placental cells has
been questioned19. Recently, a variant 35 kb upstream of the HLA-C
gene was shown to associate with differential HLA-C mRNA expres-
sion, cell-surface expression and outcome after HIV infection5–8. We
have now established a very convincing case that this 235 SNP is
marking a functional insertion/deletion variant in the 39UTR of
HLA-C that directly determines expression of the various HLA-C allo-
types differentially throughmiR-148a recognition. These data indicate
another tier of diversity to the polymorphicHLA-C locus beyond that
encoding variation in the peptide-binding region of the gene. We
suggest that disease-associated haplotypes may exert their effects
throughmultiplemechanisms, including the type of peptides they bind
and their level of expression, and that it is the combination of these that
then determines the overall susceptibility status of the haplotype.
Expression levels of differentHLA-Callotypes occur as a continuous
gradient rather than the bimodal expression pattern that would be
expected if miR-148a regulation were the sole mechanism involved.
Thus, additional cis-acting factors may fine-tuneHLA-C expression in
an allotype-specific manner. Trans-acting factors unlinked to the
HLA-C locus may also affect expression levels in a manner that is
independent of HLA-C allotype, leading to some degree of variation
in expression levels of a given HLA-C allotype. Although the system
regulatingHLA-C expression is multifactorial, the significant involve-
ment of miRNA in this process provides new approaches for mani-
pulation of the immune system in the treatment of human disease.
METHODS SUMMARY
DNA from 2,527 HIV1 patients of European descent was used to determine the
effect of the HLA-C 39UTR variation on control of HIV viral load. Viral load
measurements were obtained from participants of the Multicentre AIDS cohort
study (MACS)20, Swiss HIV Cohort (http://www.shcs.ch), the SCOPE cohort21
and the International HIV Controllers Study Cohort (http://www.hivcontrollers.
org). Individuals were grouped into those who maintain mean viral load, 2,000
(controllers) and those who have mean viral load. 10,000 (noncontrollers).
CompleteHLA-C 39UTR fragments were amplified, inserted into the XbaI site
downstream of the luciferase gene in a pGL3-control vector (Promega), and trans-
fected into B721.221, BLCL and Jurkat cells using AMAXA nucleofector (Lonza)
and into 293T cells using Fugene6 (Roche). Luciferase activity wasmeasured using
the Dual Luciferase Reporter Assay System (Promega) and presented as fold
change of relative light units22. For studies of miR-148a/miR-148b mimics and
inhibitors (Dharmacon), 20 pmol per well of oligonucleotidemimics or inhibitors
of miR-148a and miR-148b were transfected into the cells. Surface expression of
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Figure 3 | miR-148a affects cell-surface expression of HLA-C.
a–d, Histograms of HLA-C cell-surface expression on HLA-C homozygous
BLCLs using flow cytometry are illustrated. In each plot, a negative control
(NC) miRNA that does not bind to the 39UTR of HLA-C was included.
a, b,HLA-Cw*0602 homozygous cells (BLCL-Cw*0602Hom) transfected with
either a mimic or an inhibitor of miR-148a (a) or miR-148b (b). c, d, HLA-
Cw*0702 homozygous cells (BLCL-Cw*0702Hom) transfected with either a
mimic or an inhibitor of miR-148a (c) or miR-148b (d).
Table 1 | Effect of HLA-C 39UTR 263 on mean viral load
Significant independent variables P value OR 95% CI
del/del versus ins/ins 2 310214 0.33 0.25–0.43
B*2705 versus others 3 31026 0.34 0.22–0.54
B*5701 versus others 1 310212 0.21 0.14–0.32
B*5703 versus others 3 31025 0.01 0.002–0.10
B*5801 versus others 9 31024 0.27 0.12–0.59
Cw*1402 versus others 1 31024 0.26 0.13–0.52
CI, confidence interval; OR, odds ratio. N52,527. A logistic regression analysis with stepwise selection
using theHLA-C39UTR263del/del versus ins/ins comparison and 63HLA-A,B andC alleles with$1%
frequency as independent variables in the model was performed using PROC LOGISTIC (SAS 9.1
version, SAS Institute). Significance level for selecting variables shown in the table was P,0.05.
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HLA-C on BLCLs was analysed using staining with DT9 antibody (provided byV.
Braud)23.
Total RNA was extracted using the Total RNA Purification Kit (Norgen).
Relative quantification of miR-148a and miR-148b was performed using a
Taqman real-time PCR assay (Applied Biosystems) and RNU48 served as an
endogenous RNA control.
SAS9.1 (SAS Institute) was used for data management and statistical analyses.
Full Methods and any associated references are available in the online version of
the paper at www.nature.com/nature.
Received 12 March 2010; accepted 10 February 2011.
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METHODS
Subjects. DNA from 2,527 HIV1 patients of European descent was used to
determine the effect of theHLA-C 39UTR variation on control of HIV viral load.
DNA from 1,760 individuals of European descent was used to determine the
patterns of linkage disequilibrium between the HLA-C 39UTR variant and the
HLA-C coding regions. Viral loadmeasurements used in categorical analyses were
obtained from participants of the Multicentre AIDS cohort study (MACS)20, the
Swiss HIV Cohort (http://www.shcs.ch), the SCOPE cohort21, and the
International HIV Controllers Study Cohort (http://www.hivcontrollers.org).
Subjects were classified as HIV controllers if plasma HIV RNA was below 2,000
copies per ml in a minimum of three determinations in the absence of antiretro-
virals, spanning at least a 12-month period. Chronically infected individuals were
classified as noncontrollers if plasmaHIV RNAwas above 10,000 copies perml in
the absence of antiretrovirals. The respective institutional review boards approved
the study, and all subjects gave written informed consent. All of the patients were
of European descent and standard methods for measurements of viral load were
used in all three study cohorts.
HLA-C 39UTRDNA sequencing.The entireHLA-C 39UTRwas amplified from
genomic DNA by PCR using the following pair of primers: forward 59-gtgag
attctggggagctga and reverse 59-gaacagcaactaggcacagg. The amplicons were
sequenced in both directions using the same primers by capillary electrophoresis
using an ABI 3730 DNA analyser (Applied Biosystems).
HLA genotyping. DNA samples were genotyped for HLA-A, B and C genes by
sequence-based typing of exons 2 and 3 and/or the PCR-sequence-specific oligo-
nucleotide probe typing protocol as recommended by the 13th International
Histocompatibility Workshop24.
Construction of HLA-C 39UTR luciferase reporters:. The complete 39UTR
fragments from various HLA-C alleles (Cw*0303, Cw*0401, Cw*0502,
Cw*0602, Cw*0701, Cw*0702, Cw*0802, Cw*1203, Cw*1502) were amplified
from genomic DNA and inserted into the XbaI site downstream of the luciferase
gene in the pGL3-control vector (Promega). Mutations at position 307were intro-
duced using a site-directed mutagenesis kit (Stratagene) and the following sets of
primers: for 07-307C.T (sense, 59-gcaacttctacttccctaatgaagttaagaatctgaatataaat
ttgtgttc; and antisense, 59-gaacacaaatttatatt cagattcttaacttcattagggaagtaagaagttgc)
and for 07-307C.G (sense, 59-caacttcttacttccctaatgaa ttaagaagctgaatataaatttgtgtt;
and antisense, 59-aacacaaatttatattcagcttcttaacttcattagggaagtaagaagttg). The intact
miR-148-binding site was reconstituted into the Cw*0602 39UTRby altering only
the motif from positions 256–266 and the construct is referred to as 06mut
(59-CTTTACG-TGT. 5 9-ATTCATGGTGC; see Fig. 2). For the 07mut con-
struct, the miR-148-binding site of the Cw*0702 39UTRwas disrupted by altering
positions 256–266 (59-ATTCATGGTGC. 59-CTTTACG-TGT). Both 06mut
and 07mut 39UTR sequences were synthesized by Genscript.
Cell lines and culture conditions. The HLA class I negative B721.221 cell line
characterized by complete absence of HLA-A, B and C mRNA transcripts25 were
grown in RPMI 1640 (Gibco) medium with 10% heat-inactivated fetal bovine
serum (FBS; Atlanta Biologicals) and Epstein–Barr virus (EBV)-transformed B
cell lines derived from peripheral blood lymphocytes of individuals homozygous
forHLA-C alleles (BLCLs) were grown in RPMI 1640 mediumwith 15% FBS and
1% penicillin–streptomycin–glutamine (PSG; Gibco) at 37 uC in 5% CO2. The
human embryonic kidney cell line (HEK293T)26 and a T cell line (Jurkat) were
cultured in DMEM (Gibco) supplemented with 10% FBS and 1% PSG.
Cell transfection and luciferase reporter assays. B721.221, BLCLs and Jurkat
cells were plated at a density of 13 106 cells per well in a 96-well plate. 500ng per
well of the pGL3 and 20ng per well of Renilla reporter constructs were transfected
using optimized AMAXA nucleofector. 293T cells were plated at a density of
0.53 106 cells per well. 50 ng per well of the pGL3 and 2ng per well of Renilla
reporter constructs were transfected using Fugene6 (Roche Applied Bioscience).
The transfected B721.221 and BLCLs were incubated for 5 h, Jurkat cells were
incubated for 24 h, and 293T cells were incubated for 48 h at 37 uC in a CO2
incubator. The cells were lysed and the firefly and Renilla luciferase activities were
measured using the Dual Luciferase Reporter Assay System (Promega) and a
multidetection microplate reader (fluoSTAR Omega, BMG LABTECH).
Luciferase activity of each reporter construct is calculated as fold change relative
to the activity of pGL3-basic construct lacking a promoter as well as HLA-C
39UTR ((luciferase test / average luciferase basic)3 (average Renilla basic /
Renilla test)) as previously described22. The luciferase activity is presented as fold
change ofRLU6 s.e. (RLU,mean6 s.e.). Firefly luciferase activitywasnormalized
relative to theRenilla luciferase activity for each transfection. All experimentswere
performed with six replicates and repeated in at least three independent experi-
ments. Similarly, luciferase assays were carried out by co-transfecting 20 pmol per
well of oligonucleotide mimics or inhibitors of miR-148a and miR-148b
(Dharmacon) or the negative control along with the reporter plasmids. The nega-
tive control represents a universal control for both inhibitors and mimics that are
based on the sequences of miRNAs in C. elegans. These negative control miRNAs
have been confirmed to have minimal sequence identity with miRNAs in human,
mouse and rat.
Antibodies and flow cytometry. Before flow cytometry, BLCLs were plated at a
density of 13 106 cells per well in a 96-well plate and transfected with 20 pmol per
well (1mMfinal concentration) of either themimic or inhibitor ofmiR-148a, miR-
148b, or negative control using AMAXA nucleofector (Lonza). The cells were
incubated for 24–48 h in a 37 uC CO2 incubator before determining cell-surface
expression for HLA-C or HLA-B.
HLA-C surface expression on BLCLs and peripheral blood lymphocytes was
then analysed by staining with the DT9 antibody (provided by V. Braud)23 or L31
antibody (MediaPharma SRL) followed by a secondary PE-conjugated anti-mouse
IgG (Sigma-Aldrich) and collected on an LSRII flow cytometer (BD Biosciences).
Isotype controls were obtained from Sigma-Aldrich. HLA-B surface expression on
BLCLs was detected using FITC-conjugated anti-Bw4 and anti-Bw6 antibodies
(OneLambda) and FITC-conjugated isotype controls. The histogramswere plotted
using the FlowJo software version 7.5 (TreeStar). L31 binds a linear epitope onHLA
class I heavy chain alleles carrying an aromatic residue (Y/F) at position 67 (ref. 27).
These include all HLA-C allotypes used in experiments involving L31 in this study
and a few crossreacting HLA-B allotypes (HLA B7, B8, B35, B51), which were
excluded from samples chosen for our studies involving L31. L31 binds heavy
chains that are free of b2m, denatured or unfolded27.
Lymphocyte separation and miR-148a inhibition. Peripheral blood was
obtained from healthy donors and lymphocytes were separated using lymphocyte
separation medium as per manufacturer’s instructions (Lonza). The lymphocytes
were suspended in antibiotic-free RPMI 1640 medium supplemented with 10%
FBS and glutamine. PNA inhibitor ofmiR-148awas added at a final concentration
of 0.1mMfor 13 106 cells in 200ml medium and incubated for 48 h. The cells were
then analysed for surface expression of HLA-C using the DT9 antibody as
described earlier.
Immunoblot analysis.Western blot analysis was performed using protein lysates
from 103 106 BLCL cell lines transfected with mimic, inhibitor of miR-148a or
negative control (1mM final concentration, transfection conditions as described
earlier). The cellswere incubated for 48 h before the total cell lysateswere prepared.
The lysateswere subjected to SDS–polyacrylamide (Invitrogen) gel electrophoresis
and transferred to Immobilon-P membranes (Millipore). The membranes were
blocked at room temperature (20–25 uC) in 5% milk. The membranes were then
probed for HLA-C using murine monoclonal antibody L31 (MediaPharma SRL)
and b-actin (Santa Cruz Biotechnology). Horseradish peroxidase-conjugated goat
anti-mouse IgG (Santa Cruz) was used as the secondary antibody.
Isolation of RNA and miRNA expression analysis by real-time PCR. Total
RNA from B721.221 and BLCLs was extracted using the total RNA purification
kit (Norgen). Relative quantification of miR-148a, miR-148b, miR-152 and miR-
657 was performed using the Taqman real-time PCR assay (Applied Biosystems).
RNU48, a small nucleolar RNA that shows abundance and relatively stable
expression in both the cell lines used in this study, served as an endogenous control.
Statistical analyses.The effect of polymorphisms in the 39UTRofHLA-C onHIV
viral load control was determined by categorical analyses of the comparison
groups: HIV infected controllers versus noncontrollers. Stepwise logistic regres-
sionwas used to test whether anyHLA (HLA-A,B andC) allele with a frequency of
1% or greater had an effect in addition to the HLA-C 39UTR 263 effect. We used
SAS procedure PROC LOGISTIC with STEPWISE selection. Sixty-three HLA
alleles were included in the model. A likelihood ratio test was used to select alleles
into the regression model. The significance level for entry of a variable into the
model wasP, 0.05. TheHLA-C 39UTR 263del/del versus 263ins/ins comparison
and five HLA alleles met the significance level and were selected into the model.
SAS9.1 (SAS Institute) was used for data management and statistical analyses.
PROC FREQ was used to compute frequencies in each test group. PROC
LOGISTIC was used to calculate odds ratios and 95% confidence intervals. A
two sided P value of , 0.01 was considered statistically significant. PROC
ALLELE was used to compute linkage disequilibrium between the 263del/ins
SNP and HLA-C/HLA-B alleles.
24. Tilanus, M. G. J. in Immunobiology of the Human MHC. Proceedings of the 13th
International Histocompatibility Workshop and Conference (ed. Hansen, J.) Vol. 1,
304–416 (IHWG Press, 2002).
25. Shimizu, Y. & DeMars, R. Production of human cells expressing individual
transferred HLA-A,-B,-C genes using an HLA-A,-B,-C null human cell line. J.
Immunol. 142, 3320–3328 (1989).
26. Graham, F. L., Smiley, J., Russell, W. C. & Nairn, R. Characteristics of a human cell
line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36, 59–72
(1977).
27. Setini, A. et al. Distinctive features of the a1-domain alpha helix of HLA-C heavy
chains free of b2-microglobulin. Hum. Immunol. 46, 69–81 (1996).
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Supplementary Figure 1.  Predicted miRNA targeting in the 3’UTR of HLA-Cw*0702 and Cw*0602. We identified 26 different putative miRNA 
binding sites in the 3’UTR of HLA-C using Miranda27, PicTar28 and Sanger miRbase target prediction programs. RNAhybrid29 was used to select the 
best miRNA-target interactions.  The miR-148a/miR-148b binding site at position 250-272 and the miR-657 binding site at position 290-312 showed the 
strongest potential interactions as predicted by lower MFE. The predicted miRNA and miRNA-target regions are shown. 
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Cw*0702
5' U    A   G            3'
CAAA
UUC
UGGUGCACUGA         MFE -24.7
GUUU AAG  AUCACGUGACU    
miR-148a     3' U    C   AC           5‘
Cw*0303
5'      C   A            G 3'
UUC
UGGUGCGCUGA         MFE -23.0
AAG  AUCACGUGACU    
miR-148a     3' UGUUUC   AC             
5‘
Cw*0602
5'       A  U  C
G 3'
CU UA GUGUACUGA         MFE -19.0
GA AU CACGUGACU    
miR-148a     3'UGUUUCAA  C              5‘
Cw*0702  
5'U        A            G  3'
CAAA UUC  UGGUGCACUGA          MFE -24.4
GUUU AAG  ACUACGUGACU    
miR-148b     3'U    C   AC              5‘
Cw*0303
5’       C   A            G 3'                         
UUC
UGGUGCGCUGA        MFE -22.7                         
AAG  ACUACGUGACU       
miR-148b     3' UGUUUC    AC             5‘
Cw*0602
5'             CG        G   3'
UGUACUGA         MFE -17.0
ACGUGACU    
miR-148b     3' UGUUUCAAGACACU            5’
SUPPLEM
ENTARY INFORM
ATION
RESEARCH
d
oi:1
0
.1
0
3
8
/nature0
9
9
1
4
WWW.NATURE.COM/NATURE|3
Cw*0702 5'   AU  A UUA        A     3'
CCUA  GA G   AGAACCUG            MFE: -19.7 kcal/mol
GGAU  CU C   UCUUGGAC     
miR-657  3'   CU  C CAC        GG    5'
Cw*0602 5'     CU  AAAUA     U   A  3'
CCUA  GA     AGAA  CUG         MFE: -17.4 kcal/mol 
GGAU  CU     UCUU  GAC     
miR-657  3'     CU  CCCAC     G   GG 5'
307C>T 5'   AU  A UUA    U   A     3'
CCUA  GA G   AGAA CUG            MFE: -17.1 kcal/mol
GGAU  CU C   UCUU GAC     
miR-657  3'   CU  C CAC    G   GG    5'
307C>G 5'     AU  A UUA    G   A   3'
CCUA  GA G   AGAA CUG          MFE: -15.2 kcal/mol
GGAU  CU C   UCUU GAC     
miR-657  3'     CU  C CAC    G   GG  5'
Supplementary Figure 4. Predicted binding of miR-657 to the HLA-C 3’UTR. A schematic representation of 
the RNA hybrid structure of the mature miR-657 binding to the 3’UTR of Cw*0702 and Cw*0602 is shown. The 
307C/T/G polymorphism is highlighted. This polymorphism is predicted to disrupt binding of miR-657 to Cw*0602.
The minimum free energy (MFE) of the RNA duplex was analyzed by RNA hybrid.  
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Supplem
entary Figure 5.
3’UTR
 m
ediated gene regulatio
n
 is
 
consistent across different vector system
s and cell lines.
a.
3
’UTRs
 of
 C
w
*0602
and
C
w
*0702
w
ere cloned dow
nstream
 of 
R
enilla in a psicheck2 dual reporter vector. The cloned U
TR
s 
w
ere then transfected into the B721.221 cell line and luciferase 
activity w
as determ
ined after 5 hours. The luciferase activity is 
presented as the ratio of relative light units (R
LU
) of R
enilla and 
firefly luciferase, w
hich are encoded in the sam
e vector to 
norm
alize variation in transfection efficiency.  b-e. The plots show
 
the fold change in luciferase activity in B721.221 (b), BLC
L-
C
w
*0702H
om
 (EBV transform
ed B cell line derived from
 an H
LA-
C
w
*0702
hom
ozygous individual ) (c), H
EK293T (hum
an 
em
bryonic kidney cell line ) (d), and Jurkat (T cell line) (e) w
hen 
transfected w
ith the basic or control pG
L3 vectors, or w
ith the 
pG
L3 vecto
rs co
ntaining the
 3’UTR
 of
 C
w
*0602 or C
w
*0702.  The 
norm
alized luciferase activity of reporters is plotted as fold 
change of R
LU
. N
on-param
etric W
ilcoxon-M
ann-W
hitney tests 
w
ere used for statistical com
parisons and tw
o tailed p values are 
indicated. The data represent 4-6 replicates in each experim
ental 
group as show
n.  The m
ean ±SE are depicted as horizontal and 
vertical bars, respectively, for each group and one of three 
com
parable experim
ents perform
ed is show
n.
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miR-148a miR-148b miR-152RNU48
Supplementary Figure 6. miR-148b and miR-152 expression levels are 
lower than that of miR-148a. Endogenous miR-148a, miR-148b and miR-152
expression levels were estimated in the total RNA pool of three cell lines 
(B721.221, BLCL -Cw*0702Hom, BLCL-Cw*0602Hom) using a Taqman real 
time RT-PCR assay. Threshold cycles of amplification (Ct) are plotted. RNU48, 
which is expressed at constitutively high levels, served as an endogenous RNA 
control. The data represent three replicates in each group.  The Mean ±SE are 
depicted as horizontal and vertical bars, respectively, for each group.
doi:10.1038/nature0 SUPPLEMENTARY INFORMATIONRESEARCH
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Supplem
entary Figure 7.Polym
orphism
s at positions at 256, 267, and 307 in the H
LA
-C
3’UTR do not
 affect
 
post-transcriptional gene regulation.
a.Alignm
ent
 of
 partial
 3’UTR
 sequen
ces
 showing m
utatio
n
s that
 w
ere
 
introduced
 at
 positio
n
 307 (C
>T a
nd C
>G)
 into
 the
 3’UTR
 sequen
ce
 of
 H
LA-C
w
*0702
and cloned into a luciferase 
reporter. b.The graph show
s the fold change of luciferase activity (M
ean ±
SE) of the 307C
>T (07-307C
>T) and 
307C
>G
 (07-307C
>G) 3
’UTR
 rep
o
rters
 relative
 to
 the
 wild
 type
 C
w
*0702
3
’UTR rep
o
rter
.
 c. Alignm
ent of partial 
3’UTR
 sequen
ces
 showing m
utatio
n
s introduced
 at
 positio
n
s 256 a
nd 267 into
 the
 3’UTR
 sequen
ce
 of
 H
LA
-C
w
*0702
and
H
LA-C
w
*0303
and cloned into a luciferase reporter. 07/03M
ut is identical to C
w
*0702
except at positions 256 
and 267 w
here it represents the variants characteristic of C
w
*0303.  03/07M
ut is identical to C
w
*0303
except at 
positions 256 and 267 w
here it represents the variants characteristic of C
w
*0702.  d. The plot show
s the fold change 
of luciferase activity (M
ean ±
SE) of the A256C
/A267G
 m
utant of C
w
*0702 (07/03 M
ut),C
256A/G
267A m
utant of 
C
w
*0303 (03/07M
ut), w
ild type C
w
*0602, w
ild type C
w
*0702
and w
ild type C
w
*0303
3’UTR
 reporters
.
 The
 data 
represent six replicates in each experim
ental group.  The M
ean ±SE are depicted as horizontal and vertical bars, 
respectively, for each group, and one of three com
parable experim
ents perform
ed is show
n. N
on-param
etric 
W
ilcoxon-M
ann-W
hitney tests w
ere used for statistical com
parisons. ns = not significant. SUPPLEM
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C
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C
w
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C
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C
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*0401
C
w
*1203
…
.
c
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263del
Supplem
entary Figure 8.Effect of m
im
ic and inhibitor of m
iR
-148a on a panel of prim
ary lym
phocytes and B
LC
L.  a-b.
H
istogram
s show
ing the effect of H
LA
-C
 cell surface expression on various H
LA
-C
hom
ozygous B
LC
L after transfection w
ith m
im
ic 
(a) or P
N
A
 inhibitor of m
iR
-148a (b).  A
 panel of 6 B
LC
L hom
ozygous for either 263I (C
w
*0702, C
w
*0303,C
w
*0401) or 263D
 
alleles (C
w
*0602, C
w
*0802,C
w
*1203) w
ere each tested for the effects of m
im
ic and inhibitor.  c. P
rim
ary peripheral blood 
lym
phocytes hom
ozygous for 263I or 263D
 w
ere treated w
ith either P
N
A
 inhibitor of m
iR
-148a or N
C
 P
N
A
. H
LA
-C
 expression w
as 
analyzed using the D
T9 antibody and is expressed as the ratio of M
FI of D
T9/M
FI of isotype control.  N
C
 m
iR
N
A
, w
hich does not
bind to
 the 3’UTR ofH
LA
-C
, w
as included in each experim
ent. 
N
C
M
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PN
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H
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m
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m
im
ic
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inhibitor
93.55
% density
normalized to actinSupplem
entary Figure 9. Effect of m
im
ic and inhibitor of m
iR-148a on total protein levels of 
H
LA
-C
.  a. Total protein levels of H
LA-C
 as determ
ined by L31 m
Ab w
estern blot of the cell lysates 
from
 BLC
L hom
ozygous for C
w
*0602
and
C
w
*0702
are show
n. L31 antibody recognizes heavy 
chain conform
ers of H
LA-C
30(along w
ith a lim
ited num
ber of H
LA-B allotypes that w
ere selected 
against to ensure specificity of L31 binding). b-c.C
hanges in the total protein as determ
ined by L31 
w
estern blot of H
LA-C
 in the cell lysates of BLC
L hom
ozygous for C
w
*0602
(b)or C
w
*0702
(c)after 
treatm
ent w
ith N
C
, m
im
ic or inhibitor of m
iR
-148a.  The band intensities are m
easured by 
densitom
etry, and changes in the expression are norm
alized to actin and plotted as percent change 
relative to treatm
ent w
ith N
C
.  
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aCell count (%)
H
LA (log) b
c
d
e
C
w
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C
w
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B
w
4 expression 
C
w
*0602-H
om
… B
w
4 expression 
C
w
*0702-H
om
B
w
6 expression 
C
w
*0702-H
om
Supplem
entary Figure 10.  Effect of m
im
ic and inhibitor of m
iR
-148a on surface expression of free heavy 
chains of H
LA
-C
 and H
LA
-B
.  The histogram
s show
 cell surface expression of H
LA
-C
 or -B on H
LA-C
hom
ozygous 
BLCL
.
 
 In
 ea
ch plot
,
 NC
 m
iRNA
 that
 does n
ot
 bind to
 the
 3’UTR
 ofH
LA-C
or-B
w
as included. a-b. H
LA-C
 expression 
w
as m
easured by L31 binding of C
w
*0602 on BLC
L (C
w
*0602-H
om
) (a) or C
w
*0702 (C
w
*0702H
om
) (b)transfected 
w
ith either a m
im
ic or inhibitor of m
iR
-148a.  c-e.Effects of m
im
ic or inhibitor of m
iR
-148a on surface H
LA-B
expression w
as m
easured by m
Abs that recognize H
LA
-Bw
4 allotypes, including B*5701 and B*5802 (present on 
C
w
*0602-H
om
) (c)and B*4901 (present on BLC
L-C
w
*0702H
om
) (d), or Bw
-6 allotypes, including B*1801 (present in 
C
w
*0702-H
om
) (e).   
NC
m
im
ic
PN
A
 inhibitor
isotype
SUPPLEM
ENTARY INFORM
ATION
RESEARCH
d
oi:1
0
.1
0
3
8
/nature0
9
9
1
4
WWW.NATURE.COM/NATURE|10
Supplem
entary T
able S1. Frequencies of the independent variables in the logistic 
regression m
odel by stepw
ise selection of H
LA
-C
3’U
TR
 del/ins and H
LA
-A
,
-B
,
-C
alleles.  
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Supplem
entary T
able S2.  L
inkage disequilibrium
 betw
een H
LA-C
alleles and 263 del/ins from
 
the genotypes of E
uropean A
m
erican individuals (N
=1760). 
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Supplem
entary T
able S3.  L
inkage disequilibrium
 betw
een H
LA-B
alleles and 263 del/ins from
 
the genotypes of E
uropean A
m
erican individuals (N
=2521).  
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ffect of H
LA-C
3’U
T
R
 263 on H
IV
 viral load 
a.
Single point associations for H
LA-A
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,-C
loci and H
LA-C
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R
 263 w
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IV
 
viral load control 
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